| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Oxaliplatin | Oxaliplatin EP Impurity E | VE007026 | View |
| Oxaliplatin | Oxaliplatin Related Compound A (Dihydrate) | VE0010682 | View CAS 6153-56-6 |
| Oxaliplatin | Oxaliplatin Related Compound B | VE0010683 | View CAS 66900-68-3 |
| Oxaliplatin | Oxaliplatin Related Compound C | VE0010684 | View CAS 111321-67-6 |
| Oxaliplatin | Oxaliplatin Related Compound D | VE0010685 | View CAS 61758-77-8 |
Oxaliplatin Related Compound
Oxaliplatin is also used with other medications to prevent the spread of colon cancer in persons who have had surgery to remove the tumor.
References
OAndré, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., … & Haller, D. (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. Journal of clinical oncology, 27(19), 3109-3116. https://doi.org/10.1200/JCO.2008.20.6771
FAQ
How is oxaliplatin administered?
Oxaliplatin is typically administered intravenously (through a vein) in a hospital or clinic setting.
How does oxaliplatin work?
Oxaliplatin works by interfering with the DNA inside cancer cells, ultimately preventing them from dividing and growing. This leads to the death of cancer cells
What is the mechanism of action of oxaliplatin?
The mechanism of action of oxaliplatin involves the formation of DNA adducts, which interfere with DNA replication and ultimately lead to cancer cell death. Specifically, oxaliplatin forms covalent bonds with purine bases in DNA, leading to the formation of intrastrand and interstrand crosslinks, as well as DNA-protein crosslinks. These adducts cause DNA damage and activate cellular pathways that lead to cell cycle arrest, apoptosis, and autophagy.
